Navigation Links
SuperGen Reports 2008 Second Quarter Financial Results
Date:8/4/2008

stigational New Drug (IND) application with the Food and Drug Administration (FDA) of a second drug emanating from the acquired technology.

-- Additional receipts related to the sale of products to be paid by Mayne Pharma are anticipated during 2008 in a range from $1.6 million to $2.6 million. These payments will be classified as gain on sale of products.

-- Included in total operating expenses for 2008 is a reduced amount from previous guidance for non-cash stock-based compensation expense estimated at $3.5 million annually.

-- Based on the revised 2008 financial guidance loss from operations is estimated in a range from $16.6 million to $18.6 million.

-- Revised weighted average shares outstanding for 2008 are estimated at 58.1 million common shares.

Recent Corporate Events:

-- April 2008: The Company had multiple abstracts accepted for oral and

poster presentation at the American Association of Cancer Research

(AACR) Annual Meeting, that took place April 12-16 in San Diego,

California. Highlights of the presentations are included below:

-- SGI-1776, our lead pre-clinical PIM kinase inhibitor, was found to

cause tumor regression in acute myelogenous leukemia (AML) xenograft

models (Abstract No. 4974). In an oral presentation entitled, "A

potent small molecule PIM kinase inhibitor with activity in cell

lines from hematological and solid malignancies," Dr. Steven Warner,

SuperGen's Manager, Discovery Biology, detailed how scientists used

the Company's CLIMB(TM) technology to build a model that allowed for

the creation of small molecule PIM kinase inhibitors. SGI-1776 was

identified as a potent and selective inhibitor of the PIM kinases,

inducing apoptosis and cell cycle arrest, thereby causing a

reduction in phospho-BAD levels and enhancement of mTOR inhibit
'/>"/>

SOURCE SuperGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Dr. Audrey F. Jakubowski of SuperGen Retires as Chief Regulatory and Quality Officer
2. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
3. SuperGen to Announce 2007 Fourth Quarter and Fiscal Year-End Financial Results March 3, 2008
4. SuperGen Reports 2007 Fourth Quarter and Annual Financial Results
5. SuperGen to Announce 2008 First Quarter Financial Results April 28, 2008
6. SuperGen to Webcast 3rd Annual Analyst Day on April 29, 2008
7. SuperGen Reports 2008 First Quarter Financial Results
8. SuperGen to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 29, 2008
9. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
10. QMed, Inc. Reports July Medicare SNP Enrollments
11. Phlo Affiliate Reports Expanded Coverage to Oregon Border
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)...  Indianapolis-based medical device manufacturer NICO Corporation is ... products including the BrainPath® and Myriad™ technologies offering ... abnormalities and then removing affected tissue. More than ... 50 institutions throughout the United States ... in 12 abstracts, three peer-reviewed publications, and seven ...
(Date:5/4/2015)... , May 4, 2015 Tobira Therapeutics, ... on the development and commercialization of novel treatments ... completion of its merger with Regado Biosciences, Inc. ... the closing of the merger, Tobira raised $40 ... new investors and all current Tobira institutional investors, ...
(Date:5/4/2015)... AVIV, Israel , May 4, 2015  Tikcro ... filed its annual report on Form 20-F for the ... Securities and Exchange Commission ("SEC"). The annual report on ... the development of antibodies in the area of cancer ... with superior qualities of high specificity and binding in ...
(Date:5/4/2015)... , May 4, 2015  RegeneRx Biopharmaceuticals, ... announced that an independent team of researchers from ... that Thymosin B4 (TB4) plays an important role ... wounds, induced in an experimental mouse model, by ... remodeling of damaged dermal tissue.  The research found ...
Breaking Biology Technology:NICO Corporation Gains Market Expansion after Multiple Published Clinical Articles Support Access Technology for Deep Brain Lesions 2NICO Corporation Gains Market Expansion after Multiple Published Clinical Articles Support Access Technology for Deep Brain Lesions 3Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 2Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 3Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 4Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 5Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 6Tikcro Technologies Files Annual Report on Form 20-F for the Year Ended December 31, 2014 2Researchers Report that Thymosin B4 has a Major Role in Dermal Burn Wound Healing 2Researchers Report that Thymosin B4 has a Major Role in Dermal Burn Wound Healing 3
... 29 Nastech,Pharmaceutical Company Inc. (Nasdaq: NSTK ... nine-month periods ended September 30, 2007. Revenue ... $1.9 million,compared to $5.5 million for the quarter ... of $4.8 million related to our Parathyroid Hormone,(PTH1-34) ...
... Oct. 29 /PRNewswire/ - N30 Pharma (N30), a,biopharmaceutical ... respiratory drugs that target endogenous,s-nitrosothiols, today announced a ... covering the respiratory use of a s-nitrosothiol drug,candidate. ... "I am extremely pleased to announce this ...
... LA JOLLA, Calif., Oct. 29 TorreyPines Therapeutics,Inc. (Nasdaq: ... President and,Chief Executive Officer of TorreyPines, will present at ... in New York on Monday,November 5th at 9:10 a.m., ... be available live. You can,access the webcast at: ...
Cached Biology Technology:Nastech Announces Third Quarter 2007 Financial Results 2Nastech Announces Third Quarter 2007 Financial Results 3Nastech Announces Third Quarter 2007 Financial Results 4Nastech Announces Third Quarter 2007 Financial Results 5Nastech Announces Third Quarter 2007 Financial Results 6
(Date:3/31/2015)...  Elephant Talk Communications Corp. (NYSE MKT: ETAK) ("Elephant ... Defined Network Architecture (ET Software DNA® 2.0) platforms and ... $20.4 million for the year ended December 31, 2014 ... year ended December 31, 2013. At ... its multi-year transition away from its legacy landline business ...
(Date:3/30/2015)... , Mar. 26, 2015 Research and Markets ... the "Global Gesture Recognition Market in Automotive Sector ... analysts forecast the Global Gesture Recognition market in Automotive ... the period 2013-2018. Gesture recognition is the ... different gestures of an individual. Gesture recognition technology can ...
(Date:3/24/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has ... Market 2015-2019" report to their offering. ... grow at a CAGR of 23.5 percent over the ... scenario and the growth prospects of the Global Iris ... market size, the report considers the revenue generated from ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... grains with solubles (DDGS) to growing pigs, many questions are ... "Previous research shows that while the amount of energy ... lower digestibility of energy in DDGS than in corn," said ... Department of Animal Sciences. "Our goal was to find out ...
... University of Pennsylvania biologists studying human reproduction ... factor to the maternal age-associated increase in aneuploidy, ... during reproductive cell division. Using naturally aging ... of reproductive life is most likely caused by ...
... who develop life-threatening bacterial infections, or septicemia, with insulin ... infection, if results of a new preliminary study can ... online ahead of print in Diabetes Care ... oxidative stress in study participants who had been injected ...
Cached Biology News:Swine researchers seek answers to fiber's low digestibility 2Why the biological clock? Penn study says aging reduces centromere cohesion, disrupts reproduction 2Insulin may reduce several inflammatory factors induced by bacterial infection 2
... Introduction of a protein into cells permits ... signaling pathways, apoptotic pathways, and transcription factor-mediated ... studying the effects of a specific protein ... the protein directly into the cell. ProteoJuice ...
... SE flow cytometry system is the superior ... over 25 years, BD cell sorters have ... in leading university, pharmaceutical, and biotechnology research ... the research demands of today, we have ...
... is a microarray service provider ... academic researchers. We are a ... and we provide expression profiling ... arrays. Gene expression reports ...
... Control and regulate cell stretching or compression ... microscope stage. Computer controlled so you can ... the strain to produce 64 unique strain ... then the ST-150. Both models are compatible ...
Biology Products: